Omnibus VI: Cosmed debunks common misconceptions

In response to the rise in misleading information surrounding the European Omnibus VI proposal, the Cosmed association is calling for a clarification of the debate and for the facts to be re-established. Contrary to certain claims, this text does not call into question the ban on CMR substances (carcinogenic, mutagenic or reprotoxic), which is a cornerstone of the European cosmetics regulation. The aim of the measure is primarily to make operational a system of derogations that has remained unenforceable for over ten years, despite favourable scientific opinions in certain cases. It thus aims to bring regulatory decisions more closely into line with robust scientific evidence, without compromising consumer safety. Cosmed also points out that the transition periods, which are often criticised, reflect genuine technical constraints, as reformulating a cosmetic product can take several years. In practice, the proposal provides for 12 months for products to be placed on the market and 24 months for the withdrawal of affected products. For the organisation, Omnibus VI therefore stands as a measure of controlled administrative simplification. It seeks to provide legal certainty for the procedures whilst maintaining high health protection standards.